Recent Quotes (30 days)

You have no recent quotes
chg | %

Nuvo Pharmaceuticals Inc  

(Public, TSE:NRI)   Watch this stock  
Find more results for NRI
6.99
-0.01 (-0.14%)
Jun 30 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 6.95 - 7.00
52 week 4.88 - 7.15
Open 6.95
Vol / Avg. 25,384.00/20,961.00
Mkt cap 80.87M
P/E     -
Div/yield     -
EPS -0.46
Shares 11.49M
Beta -0.03
Inst. own     -
Aug 3, 2016
Q2 2016 Nuvo Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
May 12, 2016
Q1 2016 Nuvo Pharmaceuticals Inc Earnings Call
May 11, 2016
Q1 2016 Nuvo Pharmaceuticals Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 24.59% -33.35%
Operating margin 31.42% -37.81%
EBITD margin - -38.57%
Return on average assets 19.08% -11.46%
Return on average equity 23.17% -13.51%
Employees 74 -
CDP Score - -

Address

7560 Airport Rd Unit 10
MISSISSAUGA, ON L4T 4H4
Canada
+1-905-6736980 (Phone)
+1-905-6731842 (Fax)

Website links

Description

Nuvo Pharmaceuticals Inc., formerly Nuvo Research Inc., is a Canada-based healthcare company. The Company offers a range of commercial products, including Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine (HLT) patch. The Company's Pennsaid 2% is a non-steroidal anti-inflammatory drug (NSAID) containing 2% diclofenac sodium. Its Pennsaid 2% is indicated for treating the pain of osteoarthritis (OA) of the knee and also acute strains and sprains. The Company's Pennsaid is a topical pain product, which is used to treat the signs and symptoms of OA of the knee. The Pennsaid combines the transdermal carrier with diclofenac sodium, which is a NSAID and delivers the active drug through the skin at the site of pain. Its HLT Patch is a topical patch that combines lidocaine, tetracaine and heat, using Controlled Heat-Assisted Drug Delivery (CHADD) technology. HLT Patch provides local analgesia prior to painful needle procedures, such as dialysis, blood draws and pediatric needles.

Officers and directors

Daniel H. Chicoine Chairman of the Board, Co-Chief Executive Officer
John C. London President, Co-Chief Executive Officer, Director
Stephen L. Lemieux Chief Financial Officer, Vice President
Henrich R. K. Guntermann M.D. President of Europe and Immunology Group, Director
Katina Loucaides Vice President, General Counsel, Secretary
Jesse Ledger Vice President - Business Development
David A. Copeland Lead Independent Director
Samira Sakhia CPA Director
Anthony E. Dobranowski Independent Director
Jacques Messier Independent Director